Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neoadjuvant chemotherapy for osteosarcoma].

Wei Guo1, Rong-li Yang, Xiao-dong Tang

  • 1Musculoskeletal Tumor Center, People's Hospital, Peking Universality, Beijing 100044, China.

Zhonghua Yi Xue Za Zhi
|September 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Prospects of Ursolic Acid in Colorectal Cancer: Modulation of the Wnt/β-Catenin Signaling Pathway and Gut Microbiota Composition.

The American journal of Chinese medicine·2025
Same author

Bioactive ligands targeting ectopic olfactory receptors: Implications for therapeutic strategies.

British journal of pharmacology·2025
Same author

Development of a global forearm reconstruction system for post-tumor resection defects of the radius or ulna: a proof-of-concept study.

Frontiers in bioengineering and biotechnology·2025
Same author

Non-volatile and multistate terahertz response in semi-floating-gate graphene field-effect transistors.

Optics express·2025
Same author

Dry-processed composite cathode design with fast electron transfer network for high energy density lithium-ion battery.

Journal of colloid and interface science·2025
Same author

Scalable Top-Down Approach for Recycling Highly Degraded Spent LiFePO<sub>4</sub> via Lattice Fragmentation-Regeneration.

Small (Weinheim an der Bergstrasse, Germany)·2024

Neoadjuvant chemotherapy for osteosarcoma, including high-dose methotrexate (MTX), followed by surgery, improves outcomes. Second-line drugs like ifosfamide and paclitaxel enhance effectiveness in poor responders, increasing survival rates.

Area of Science:

  • Orthopedic Oncology
  • Medical Oncology
  • Surgical Oncology

Context:

  • Osteosarcoma is a primary bone malignancy often treated with neoadjuvant chemotherapy.
  • Effective neoadjuvant chemotherapy protocols are crucial for improving surgical outcomes and patient survival.
  • Evaluating treatment responses and adapting chemotherapy regimens is essential for managing osteosarcoma.

Purpose:

  • To summarize the clinical experience and outcomes of neoadjuvant chemotherapy for osteosarcoma.
  • To assess the efficacy of high-dose methotrexate (MTX) and subsequent treatment modifications.
  • To evaluate the impact of different surgical reconstruction methods on tumor relapse.

Summary:

  • 113 osteosarcoma patients received neoadjuvant chemotherapy (high-dose MTX) followed by surgery.

Related Experiment Videos

  • Chemotherapy response varied, with 60 excellent, 35 good, and 18 poor responses.
  • Prosthetic replacement showed lower relapse rates (8.3%) compared to reimplantation (55%).
  • The 5-year survival rate was 71.93%, with lung metastasis rates correlating inversely with chemotherapy response.

    • Impact:

    • Neoadjuvant chemotherapy regimens incorporating second-line agents (ifosfamide, paclitaxel) are more effective for poor responders.
    • Prosthetic replacement is associated with a significantly lower risk of tumor relapse compared to devitalized tumor bone reimplantation.
    • The study highlights the importance of tailored neoadjuvant chemotherapy and surgical strategies in optimizing osteosarcoma treatment outcomes.